MRI-Based Radiomics Model for Pretreatment Prediction of Pathological Lymph Node Metastasis in Neuroendocrine Carcinoma of the Cervix: Dual-Center Development and External Validation.
5 affiliations
- 1Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
- 2Innovation Center for Cancer Research, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
- 3Fujian Key Laboratory of Advanced Technology for Cancer Screening and Early Diagnosis, Fuzhou 350014, China.
- 4Department of Radiology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
- 5Department of Obstetrics and Gynecology, Fujian Provincial Hospital, Fuzhou 350001, China.
Abstract
Objectives: To develop and externally validate MRI-based radiomics and clinicoradiomics models for predicting pathological lymph node metastasis (LNM) in neuroendocrine carcinoma of the cervix (NECC). Methods: This retrospective two-center study included 133 patients who underwent pretreatment pelvic MRI and pathological nodal assessment: 93 for development and 40 for external validation. Intratumoral and peritumoral features were extracted from T2-weighted, diffusion-weighted, and contrast-enhanced T1-weighted images. Stratified nested fivefold cross-validation evaluated the complete revised selection process. Locked models were assessed for discrimination, calibration, and exploratory net benefit, with conventional MRI nodal assessment as a comparator. Results: Pathological LNM was present in 54/133 patients (40.6%). The selected radiomics-only k-nearest neighbors (KNN) model had an external AUC of 0.783 (95% CI, 0.630 to 0.935), accuracy of 0.800, sensitivity of 0.813, and specificity of 0.792. The complete selection procedure yielded an out-of-fold AUC of 0.731. External AUCs were 0.727 for the clinical/MRI model and 0.767 for the clinicoradiomics model; neither fusion model differed significantly from the clinical/MRI comparator. Conventional MRI sensitivity was 0.563, with no significant paired difference from the selected model (p = 0.125). External calibration was imperfect (Brier score, 0.186; slope, 0.672). Conclusions: MRI radiomics showed moderate external discrimination of pathological LNM in NECC. Adding clinical variables did not demonstrate further benefit. Multicenter validation, recalibration, and clinical-impact assessment are needed before clinical application.
Related
- A Pathological Image-Based Pathomics Signature Combined with Clinicopathological Features for Predicting Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma: A Development and External Validation Study
- Machine learning prediction model for distant metastasis at diagnosis in pediatric neuroblastoma: development, interpretation, and temporal validation
- Development and internal validation of a clinicopathological and CT radiomics based prediction model for extracranial distant metastasis after radical resection in early-stage non-small cell lung cancer
- Development and internal validation of a pretreatment magnetic resonance imaging-based radiomics prediction model for 1-year overall survival in treatment-naïve patients with hepatocellular carcinoma receiving transarterial chemoembolization combined with targeted therapy and immune checkpoint inhibitors.
- Development and Patient-Level Internal Validation of an MRI-Based Radiomics Machine Learning Model for Preoperative Prediction of Cervical Lymph Node Metastasis in Oral Squamous Cell Carcinoma: A Pilot Study.
BibTeX
@article{chen2026mribased,
title = {{MRI-Based Radiomics Model for Pretreatment Prediction of Pathological Lymph Node Metastasis in Neuroendocrine Carcinoma of the Cervix: Dual-Center Development and External Validation.}},
author = {Jian Chen and Fengle Jiang and Xingfa Chen and Rong Lin and Ning Ma and Haijuan Yu and Yang Sun},
journal = {Current oncology (Toronto, Ont.)},
year = {2026},
month = oct,
doi = {10.3390/curroncol33100625},
url = {https://europepmc.org/article/MED/42930192},
note = {CC BY},
}
RIS
TY - JOUR
TI - MRI-Based Radiomics Model for Pretreatment Prediction of Pathological Lymph Node Metastasis in Neuroendocrine Carcinoma of the Cervix: Dual-Center Development and External Validation.
AU - Jian Chen
AU - Fengle Jiang
AU - Xingfa Chen
AU - Rong Lin
AU - Ning Ma
AU - Haijuan Yu
AU - Yang Sun
PY - 2026
DA - 2026/10/16
JO - Current oncology (Toronto, Ont.)
DO - 10.3390/curroncol33100625
UR - https://europepmc.org/article/MED/42930192
AB - Objectives: To develop and externally validate MRI-based radiomics and clinicoradiomics models for predicting pathological lymph node metastasis (LNM) in neuroendocrine carcinoma of the cervix (NECC). Methods: This retrospective two-center study included 133 patients who underwent pretreatment pelvic MRI and pathological nodal assessment: 93 for development and 40 for external validation. Intratumoral and peritumoral features were extracted from T2-weighted, diffusion-weighted, and contrast-enhanced T1-weighted images. Stratified nested fivefold cross-validation evaluated the complete revised selection process. Locked models were assessed for discrimination, calibration, and exploratory net benefit, with conventional MRI nodal assessment as a comparator. Results: Pathological LNM was present in 54/133 patients (40.6%). The selected radiomics-only k-nearest neighbors (KNN) model had an external AUC of 0.783 (95% CI, 0.630 to 0.935), accuracy of 0.800, sensitivity of 0.813, and specificity of 0.792. The complete selection procedure yielded an out-of-fold AUC of 0.731. External AUCs were 0.727 for the clinical/MRI model and 0.767 for the clinicoradiomics model; neither fusion model differed significantly from the clinical/MRI comparator. Conventional MRI sensitivity was 0.563, with no significant paired difference from the selected model (p = 0.125). External calibration was imperfect (Brier score, 0.186; slope, 0.672). Conclusions: MRI radiomics showed moderate external discrimination of pathological LNM in NECC. Adding clinical variables did not demonstrate further benefit. Multicenter validation, recalibration, and clinical-impact assessment are needed before clinical application.
SN - 1198-0052
SN - 1718-7729
ER -